or
forgot password

    • cancer clinical trials in alabama

    • Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
    Children's Hospital of Alabama
    Birmingham, Alabama 35233
    Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Pleomorphic Xanthoastrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Unspecified Childhood Solid Tumor, Protocol Specific
    A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
    Clearview Cancer Institute
    Huntsville, Alabama 35805
    Chronic Lymphocytic Leukemia
    Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
    University of Alabama at Birmingham

    Trial Locations
    University of Alabama at Birmingham
    Children's Hospital of Alabama
    Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
    Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Brain Tumor
    An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Cushing's Disease
    A Study in Recurrent Glioblastoma (GB)
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Birmingham, Alabama 35294
    Glioblastoma
    Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
    Investigational Site Number 840010
    Birmingham, Alabama 35205
    Neoplasm Malignant
    Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
    Children's Hospital of Alabama

    Trial Locations
    Children's Hospital of Alabama
    University of South Alabama
    B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Diffuse Large Cell Lymphoma, L3 Childhood Acute Lymphoblastic Leukemia, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Untreated Childhood Acute Lymphoblastic Leukemia
    Effects of HQK-1001 in Patients With Sickle Cell Disease
    University of South Alabama
    Mobile, Alabama 36693
    Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
    Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
    Radiant Research

    Trial Locations
    Radiant Research
    Birmingham Heart Clinic
    Central Alabama Research
    Digestive Health Specialists of the Southeast
    Coastal Clinical Research
    Obesity, Overweight
    Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
    University of Alabama at Birmingham

    Trial Locations
    University of Alabama at Birmingham
    The Kirklin Clinic at Acton Road
    HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
    Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805
    Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Primary Central Nervous System Lymphoma
    NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Renal Cell Carcinoma
    Afatinib Expanded Access Program
    1200.45.004 Boehringer Ingelheim Investigational Site
    Mobile, Alabama
    Carcinoma, Non-Small-Cell Lung
    The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
    Achieve Clinical Research, LLC
    Tuscaloosa, Alabama 35406
    Pain, Peripheral Neuropathy, Neuropathic Pain
    Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
    Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
    Universeity of Alabama Cancer Center
    Birmingham, Alabama 35294
    Breast Neoplasms
    The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Cholangiocarcinoma
    A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
    Synta Pharmaceuticals Investigative Site
    Birmingham, Alabama 35249
    Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer
    TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome)
    Lexicon Investigational Site
    Mobile, Alabama 36604
    Carcinoid Syndrome
    Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
    Research Site
    Alabaster, Alabama
    N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
    Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    High Risk Acute Myeloid Leukemia
    Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+ Metastatic Breast Cancer
    University of Alabama Comprehensive Cancer Center SC
    Birmingham, Alabama 35294
    Hormone Receptor Positive Breast Cancer
    Belimumab Assessment of Safety in SLE
    GSK Investigational Site
    Birmingham, Alabama 35209
    Systemic Lupus Erythematosus
    Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
    Children's Hospital of Alabama
    Birmingham, Alabama 35233
    Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Childhood Solid Tumor, Protocol Specific
    To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
    Investigational Site Number 840070

    Trial Locations
    Investigational Site Number 840070
    Investigational Site Number 840138
    Rheumatoid Arthritis
    Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
    University of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35233
    Lupus Nephritis
    A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Hodgkin Disease
    Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors
    Children's Hospital of Alabama
    Birmingham, Alabama 35233
    Unspecified Childhood Solid Tumor, Protocol Specific
    Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
    University of Alabama - Birmingham
    Birmingham, Alabama 35294
    Cutaneous T-Cell Lymphoma
    Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
    University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300
    Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
    Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
    Clearview Cancer Center
    Huntsville, Alabama 35801
    Leukemia Lymphocytic Chronic B-Cell
    Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Clearview Cancer Institute
    Huntsville, Alabama 35805
    Leukemia Lymphocytic Chronic B-Cell
    Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.
    University of Alabama Comprehensive Cancer Center University of Alabama (8)
    Birmingham, Alabama 35294
    CML